Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $14
Altimmune Q3 EPS $(0.15) Misses $(0.14) Estimate, Sales $0 Miss $1.400K Estimate
Altimmune's Pemvidutide Meets Primary Endpoint in Phase 2 Alcohol Use Disorder Trial
Loading...